SERVICE

KEYWORD

CONTACT US

Main Office, PCL

Address: Haimen Biotech and Pharmaceutical Park, Riverside New District, Haimen, Jiangsu Province, China

Tel:+86 0513 68015200

Email:infor@pharmacorelab.com
Website: www.pharmacorelab.com


Branch Office, PCL

Address: Block 6D, 780 Cailun Road, China (Shanghai) pilot free trade zone. infor@pharmacorelab.com

CiPA panel

Your current location: Home > SERVICE > Preclinical cardiac safety ass > CiPA panel

hERG

Time2020-04-20 14:07:09 Hits312


hERG channel is critical in the repolarization stage of the heart. Congenital mutation or drug inhibition of hERG channel could prolong QT interval in ECG, which potentially cause TdP (Torsades de pointes), a fatal type of polymorphic ventricular tachycardia in severe cases. On the other hand, significant drug potentiation of hERG channel could shorten QT interval, leading to cardiac arrhythmia as well.

PharmaCore Labs provides manual patch clamp functional hERG assay to evaluate drug's inhibition or potentiation effect on hERG channel.


In vitro electrophysiology functional hERG assay with manual patch clamp:


Assay platform/method

Conventional patch clamp

Cells used in the assay

HEK293 hERG stable cell line

Measured parameters

Whole cell tail current of hERG channels

Test concentrations

5 doses for IC50

Data point repeats

N ≥ 3 for each concentration


Note: 1) Positive control: 30 μM Quinidine is used in the assay to ensure cell quality and normal response.

          2) 1 or 2 doses could be tested if IC50 is not required.





Inhibition effect of different concentrations of quinidine on hERG tail currents



The stability curve of hERG IC50 of quinidine over years

  • Previous:Nav1.5
  • Next: no more
  • Copyright © 南通科瑞斯生物医药科技有限公司 All rights reserved 备案号:苏ICP备15051795号 欢迎来电咨询! 技术支持:裕福科技